Lynn O’Donnell

Lynn O'Donnell's work focuses on cellular therapies for blood cancers, including stem cell transplantation, dendritic cell vaccines for multiple myeloma, and engineered immune cells like CAR-T cells for lymphoid cancers. Much of the research addresses the practical and regulatory side of manufacturing these therapies, such as quality control, facility management, and compliance with FDA and cGMP (good manufacturing practice) standards. This work is largely conducted through large multicenter clinical trials and academic medical center cell therapy facilities.

Publication output has grown substantially over the last decade, rising from a handful of papers per year before 2020 to a notable peak of 14-15 publications in 2023-2024.

Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026